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Context: Low adiponectin concentrations are associated with the presence of an adverse cardio-
vascular disease (CVD) risk profile.
Objective: We studied the predictive value of adiponectin levels for all-cause and CVD mortality
and CVD morbidity.
Design, Setting, and Participants: This was a population-based cohort study in Hoorn, The Neth-
erlands, which started in 1989 and included 2484 participants, aged 50–75 yr.
Main Outcome Measures: Hazard ratios (HRs) with 95% confidence interval per SD change in
log-adiponectin for all-cause and CVD mortality and CVD morbidity were calculated.
Results:Adiponectinwas determined for 1077men and 1248women. Higher adiponectin reduced
the risk of nonfatal CVD in women [HR with 95% confidence interval 0.72 (0.61–0.90) in women
and 0.92 (0.79–1.06) in men], but not the risk of all-cause or CVD mortality. In contrast, after
adjustment for cardiovascular risk factors, higher adiponectin was a significant predictor of all-
cause and CVDmortality [HR for CVDmortality 1.45 (1.10–1.92) in women and 1.30 (1.04–1.63) in
men]. Higher adiponectin was associated with an increased risk of CVD mortality in people with
prevalent CVD [HR 1.27 (0.98–1.63)] andwith reduced risk in peoplewithout [HR 0.90 (0.73–1.11)].
After adjustment for cardiovascular risk factors, the HRs for CVD mortality were 1.60 (1.14–2.23)
for patients with and 1.38 (1.06–1.80) for patients without prevalent CVD.
Conclusions: High levels of adiponectin predict mortality, in particular in patients with prevalent
CVD. We hypothesize that adiponectin protects against metabolic and vascular diseases, but in
patients already afflicted with CVD, adiponectin is compensatory up-regulated and, therefore,
indicates a high mortality risk. (J Clin Endocrinol Metab 93: 1489–1496, 2008)
Adiponectin is an adipocytokine, which is mainly producedby the adipose tissue (1). Although it is the most abun-
dantly produced protein of the fat cell, plasma levels are reduced
in obese patients. There is growing evidence that reduced adi-
ponectin concentrations indicate an increased cardiovascular
risk because hypoadiponectinemia is associated with the com-
ponents of the metabolic syndrome, in particular with insulin
resistance, elevated triglycerides, and low high-density lipopro-
tein (HDL) (1, 2). Apart from this, adiponectin possesses anti-
inflammatory properties and exerts direct antiatherosclerotic
and cardioprotective effects (2). Clinical studies have shown that
low adiponectin concentrations are associated with endothelial
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dysfunction, increased carotid intima-media thickness, and cor-
onary artery disease (2–4). High adiponectin concentrations are
independent of other cardiovascular risk factors associated with
a lower prevalence of acute coronary syndromes (4). Therefore,
it was suggested that low adiponectin concentrations are a car-
diovascular risk factor and that therapeutic strategies that en-
hance the secretion or action of this adipocytokine might reduce
the incidence of cardiovascular diseases (CVDs) (1, 2).
However, several recently published studies on the prospec-
tive association between adiponectin and CVD events/mortality
showed inconsistent results. Five studies reported that adiponec-
tin was not independently associated with future CVD (5–9).
Low adiponectin concentrations turned out as a risk factor for
future CVD in some studies (10–16), whereas others showed
that high adiponectin levels were associated with an increased
risk of CVD and/or mortality (17–23). The underlying mecha-
nisms for these contradictory results are still unclear but may be
due to differences in the study populations. Toward this, it was
speculated that low adiponectin predicts cardiovascular events
in low-risk populations for CVD, whereas in high-risk popula-
tions, a counter-regulatory increase of adiponectin occurs that is
responsible for the elevated cardiovascular risk associated with
high adiponectin levels (24, 25). To test this hypothesis, we stud-
ied the association of adiponectin with 15-yr all-cause and CVD
mortality and 10-yr nonfatal CVD in the Hoorn Study, a large
population-based study, distinguishing subjects with and with-
out a history of CVD.
Subjects and Methods
Study population
The Hoorn Study is a Dutch cohort study of diabetes and diabetes
complications in the general population, which started in 1989. The
cohort and the baseline measurements have been described in detail pre-
viously (26). Briefly, a random selection of 3553 men and women of
50–75 yr old was taken from the population register. A total of 2540
(71.5%) agreed to participate, and after exclusion of 56 non-Caucasian
participants, the Hoorn Study population consisted of 2484 men and
women. For the present study, we excluded 159 subjects with missing
adiponectin data, leaving 1077 men and 1248 women for the analyses.
This number of study probands was not determined by power calcula-
tions for specific hypotheses.All participants gave theirwritten informed
consent. The study was approved by the Ethics Committee of the Vrije
Universiteit Medical Center.
Baseline examination and measurements
At the baselinemedical examination, a blood sample was taken from
all participants after overnight fasting. Adiponectin was determined in
2004 in spare baseline plasma samples that hadbeen stored at80Cand
had never been thawed before. Adiponectin was determinedwith a latex
turbidometric immunoassay. The interassay and intraassay coefficients
of variation were less than 2.0% and less than 3.1%, respectively. A
standard 75-g oral glucose tolerance test was performed in all subjects,
except those using glucose-lowering medication. Plasma glucose was
determined with a glucose dehydrogenase method (Merck, Darmstadt,
Germany). Diabetes and impaired glucose metabolism were defined ac-
cording to World Health Organization criteria of 1999 (27). Fasting
insulin was determined with an insulin-specific double-antibody RIA
(antibody: LINCOSP21; LINCOResearch, Inc., St. Louis,MO). Fasting
triglycerides, and total and HDL-cholesterol were determined by enzy-
matic techniques (Roche Molecular Biochemicals, Mannheim, Ger-
many). Serumalanine aminotransferase (ALT) enzyme activitywasmea-
sured according to themethod of the International Federation ofClinical
Chemistry from 1985, and expressed as U/liter. Serum creatinine level
was determined in mol/liter, and renal function [glomerular filtration
rate (GFR)] was estimated by the Cockcroft-Gault formula in ml/
min1.73 m2.
Waist and hip circumference, weight, and height were measured.
Body mass index (BMI) was calculated as the ratio of weight and height
squared. Blood pressure was measured twice on the right arm with a
random-zero sphygmomanometer (Hawksley-Gelman Ltd., Lancing,
UK), and themeanwas used for computations. Information about use of
medication, including antihypertensive medication, smoking status
(nonsmokers, ex-smokers, and current smokers), and history of CVD at
baseline (assessed by Rose Questionnaire) were determined by a self-
administered questionnaire. Cigarette-yearswere calculated as the prod-
uct of years smoked and mean number of cigarettes per day.
Follow-up of morbidity and mortality
The cohort was followed with respect to morbidity and mortality.
Vital status was obtained from the population register of the city of
Hoorn. Causes of death were coded by reviewing death certificates, and
nonfatal CVD events were classified using medical records of general
practitioners and the local hospital. Causes of death were coded accord-
ing to the International Classification of Diseases, Injuries and Causes of
Death, ninth revision.
CVDmortality was defined with International Classification of Dis-
eases, Injuries and Causes of Death codes 390–459 (diseases of the cir-
culatory system) or 798 (sudden death, cause unknown) because sudden
death in general is of CVD origin. Vital status until January 2004 was
known for all subjects. Cause of death could not be obtained for 35 men
and 28 women.
Data on nonfatal outcomes were complete until 2000, for 845 men
and 909womenwho gave permission to access their hospital files and/or
contact their general practitioners. Nonfatal CVD was defined as doc-
umented angina pectoris (chest pain, followed by coronary artery bypass
surgery or angioplasty, or in the presence of more than 50% stenosis or
electrocardiographic changes or positive exercise test), myocardial in-
farction (in the presence of at least two of the following: typical pain,
elevated enzymes, and/or electrocardiogram changes), congestive heart
failure (in the presence of at least two of the following: shortness of
breath, cardiomegaly, dilated neck veins, or one of the former in the
presence of edema or tachycardia), stroke or transient ischemic attack
(sudden onset of symptoms, neurological symptoms, or change of con-
sciousness), or peripheral disease (by procedure or typical pain accom-
panied by stenosis or ankle arm blood pressure ratio 0.90 or positive
vascular stress test).
Statistical analyses
Population characteristicswere comparedbetween sex-specific quar-
tiles of baseline plasma adiponectin levels. Analyses were performed
separately for men and women because of the different fat distribution
in women and because women have higher levels of adiponectin than
men. For proportions, trends over the quartiles were tested with the 2
test withP for linear-by-linear test. For continuous variables the Pearson
and age-adjusted partial correlations with the log of adiponectin were
determined. Survival curves of 15-yr all-cause mortality and CVD mor-
tality and 10-yr nonfatal CVD in quartiles of adiponectin were plotted.
Age-adjusted hazard ratios (HRs) for all-cause mortality, CVD mortal-
ity, and nonfatal CVD for the second through the fourth quartile relative
to the lowest quartile of adiponectin were estimated with Cox propor-
tional hazards analyses. We first adjusted for all possible mediating or
confounding variables one by one, and then combined all these variables
into onemodel. To study the possible modifying effect of the presence of
diabetes or prevalentCVD, stratified analyseswere performed.AP value
less than 0.05was considered statistically significant. Statistical analyses
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were performed with SAS for windows, version 8.0 (SAS Institute Inc.,
Cary, NC) and with SPSS, version 15.0 (SPSS, Inc., Chicago, IL).
Results
Mean adiponectin was higher in women than men, and was
increasingwith age and lowerGFR inboth genders (Tables 1 and
2). High adiponectin was strongly associated with a more fa-
vorable CVD risk profile, with lower weight, smaller waist,
higher HDL cholesterol and lower triglycerides, lower insulin
and glucose levels, and lower ALT. Associations were not sig-
nificant for total cholesterol. Inwomen therewas a trendof lesser
smoking and higher participation in sports activities with higher
levels of adiponectin. In men the reverse was observed for smok-
ing, and there was no significant association with sports activi-
ties.Adiponectinwasnot associatedwithprevalentCVDatbase-
line. The baseline characteristics according to adiponectin
quartiles for study participantswith andwithout prevalent CVD
are shown in supplemental Tables A and B (published as sup-
plemental data on The Endocrine Society’s Journals Online web
site at http://jcem.endojournals.org).
Until January 2004, after 15-yr follow-up, 286 men and 219
women had died, among whom 121 men and 83 women due to
CVD. Until January 2000, after 10-yr follow-up, 195 men and
128 women had a nonfatal CVD event. As shown in Fig. 1,
all-causemortality was highest in bothmen andwomenwith the
highest adiponectin levels. The higher risk ofmortality could not
be attributed to any particular causes, and the association was
also observed for cancer mortality, and noncancer non-CVD
mortality (data not shown).
As shown in Table 3, adjustment for age did not explain the
positive association between adiponectin and all-causemortality
in men. In women, but not in men, there was a U-shaped asso-
ciation with all-cause and CVDmortality, and a significant neg-
ative associationwithnonfatalCVDwasobserved inwomenand
anonsignificant trend inmen.Adjustment forpossiblemediating
or confounding variables resulted in a strong and statistically
significant increased risk of CVD mortality with higher adi-
ponectin level for both men and women (Table 4). The same
pattern was observed for all-cause mortality and for nonfatal
CVD (data not shown).
When we stratified for the presence of type 2 diabetes, no
differences were observed in the relationships for all-cause and
CVD mortality, or for nonfatal CVD (data not shown). For all-
cause andCVDmortality analysesof the entire studypopulation,
we observed P values for interaction terms of prevalent CVD
with dummy variables of adiponectin quartiles all less than 0.15.
Therefore, we performed subgroup analyses and found that high
adiponectin was associatedwith increasedmortality risk in both
sexes with prevalent CVD at baseline (Table 5). In women with-
out prevalent CVD, the mortality risk was reduced in higher
adiponectin quartiles, and in men there was a U-shaped associ-
TABLE 1. Baseline characteristics for women according to quartiles of adiponectin
Quartiles of adiponectin Partial
correlationa P valueb1 (n  310) 2 (n  314) 3 (n  311) 4 (n  313)
Adiponectin (g/liter) 8.10  1.59 12.10  1.07 16.01  1.28 24.61  5.87
Age (yr) 61.2  7.3 60.9  7.4 61.7  7.3 63.6  7.5 0.154 0.001
BMI (kg/m²) 27.9  4.0 27.5  4.1 26.4  4.1 25.7  3.5 0.235 0.001
WHR 0.88  0.07 0.85  0.07 0.84  0.07 0.82  0.07 0.360 0.001
Waist (cm) 91.1  10.3 88.6  10.8 86.3  10.1 83.3  10.2 0.307 0.001
Hip (cm) 103.4  7.5 103.8  7.9 102.6  7.7 101.9  7.4 0.090 0.004
Use of antihypertensives (%) 31.3 25.5 14.2 19.5 0.001
Diastolic bp (mm Hg) 82.6  10.7 80.9  10.2 80.0  10.4 79.7  10.8 0.121 0.001
Systolic bp (mm Hg) 138.5  21.5 134.4  20.9 134.2  20.6 133.4  20.7 0.143 0.001
Cholesterol (mmol/liter) 7.02  1.35 6.78  1.18 6.88  1.17 6.82  1.15 0.038 0.232
HDL cholesterol (mmol/liter) 1.23  0.90 1.40  0.33 1.50  0.31 1.65  0.39 0.449 0.001
Triglycerides (mmol/liter) 2.09  1.22 1.56  1.02 1.33  0.53 1.21  0.54 0.417 0.001
Insulin (pmol/liter) 104.9  52.0 88.8  51.4 77.5  33.2 76.3  41.5 0.260 0.001
Glucose (mmol/liter) 6.23  2.20 5.72  1.67 5.53  1.21 5.41  1.40 0.221 0.001
2-h glucose (mmol/liter) 7.24  3.84 6.34  3.10 5.85  2.92 5.50  1.93 0.275 0.001
HbA1c (%) 5.77  1.16 5.49  0.86 5.40  0.70 5.35  0.69 0.190 0.001
GFR (ml/min1.73 m²) 75.9  18.2 73.7  15.7 70.5  14.6 67.6  14.2 0.155 0.001
ALT (IU/liter) 12.7  12.6 11.0  5.8 11.2  6.1 10.0  4.8 0.137 0.001
Current cig smoker (%) 37.3 28.6 27.7 19.4 0.001
Cig yearsc 270  325 219  319 212  310 163  264 0.112 0.001
Alcohol (g/d) 5.3  8.5 5.8  9.7 6.2  9.9 5.0  7.6 0.004 0.090
Sport activity (%) 25.7 26.3 30.3 33.9 0.013
CVD (%) 19.4 16.9 11.9 17.4 0.235
Continuous data are presented as means  SD and categorical data as percentages. bp, Blood pressure; Cig, cigarette; HbA1c, glycosylated hemoglobin; WHR, waist to
hip ratio.
a Partial (Pearson) correlations are age adjusted, except for age.
b P values are for partial correlation coefficients for continuous variables, or for the  2 test with P for linear-by-linear test for proportions.
c Product of number of cigarettes per day and years smoked.
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ation with reduced risk in the second and increased risk in the
third and fourth adiponectin quartile. After adjustments for car-
diovascular risk factors (according to the fully adjustedmodel in
Table 4), the HR [with 95% confidence interval (CI)] for car-
diovascularmortality includingboth sexeswas1.38 (1.06–1.80)
for patientswithout and1.60 (1.14–2.23) for patientswithCVD
per SD change in log adiponectin. Accordingly, the HR for all-
cause mortality was 1.33 (1.15–1.55) for patients without and
1.69 (1.33–2.16) for patients with prevalent CVD, with similar
results for sex-stratified analyses (data not shown).
FIG. 1. A, Fifteen-year all-cause mortality according to quartiles (quart) of adiponectin in women. B, Fifteen-year all-cause mortality according to quartiles of
adiponectin in men.
TABLE 2. Baseline characteristics for men according to quartiles of adiponectin
Quartiles of adiponectin Partial
correlationa P valueb1 (n  267) 2 (n  261) 3 (n  277) 4 (n  272)
Adiponectin (g/liter) 5.54  0.95 7.85  0.60 10.27  0.83 15.58  3.71
Age (yr) 58.3  6.3 60.5  6.8 61.7  7.4 63.7  7.2 0.208 0.001
BMI (kg/m²) 27.0  2.9 26.7  2.9 25.9  2.9 25.1  2.7 0.264 0.001
WHR 0.96  0.06 0.96  0.06 0.94  0.07 0.93  0.06 0.250 0.001
Waist (cm) 97.1  8.5 96.8  8.7 94.6  9.4 92.4  8.7 0.255 0.001
Hip (cm) 101.0  5.5 100.8  5.3 100.1  5.3 99.0  5.3 0.151 0.001
Use of antihypertensives (%) 21.0 19.5 20.6 8.8 0.001
Diastolic bp (mm Hg) 84.6  9.2 84.0  9.2 83.0  9.9 82.7  11.0 0.094 0.006
Systolic bp (mm Hg) 135.1  18.1 134.8  18.3 133.7  17.7 136.9  21.4 0.084 0.015
Cholesterol (mmol/liter) 6.37  1.12 6.47  1.14 6.34  1.08 6.48  1.13 0.042 0.221
HDL cholesterol (mmol/liter) 1.07  0.29 1.13  0.24 1.18  0.29 1.32  0.34 0.304 0.001
Triglycerides (mmol/liter) 2.06  1.41 1.75  0.87 1.53  0.71 1.38  0.70 0.247 0.001
Insulin (pmol/liter) 97.5  53.2 95.3  61.5 88.1  59.6 74.2  49.7 0.190 0.001
Glucose (mmol/liter) 5.95  1.44 5.95  1.57 5.71  1.18 5.55  1.15 0.199 0.001
2-h glucose (mmol/liter) 6.61  3.40 6.07  3.20 5.53  2.45 5.27  1.87 0.220 0.001
HbA1c (%) 5.54  0.84 5.51  0.91 5.42  0.66 5.47  0.69 0.096 0.006
GFR (ml/min1.73 m²) 86.4  16.9 80.8  14.4 78.8  16.5 74.5  17.7 0.133 0.001
ALT (IU/liter) 17.8  13.3 14.8  8.9 13.6  6.7 12.3  7.8 0.157 0.001
Current cig smoker (%) 33.8 37.6 38.9 36.7 0.456
Cig yearsc 433  405 505  444 507  422 563  558 0.087 0.012
Alcohol (g/d) 14.4  15.0 14.0  16.2 11.1  12.8 11.7  13.2 0.046 0.184
Sport activity (%) 28.6 23.9 25.8 21.8 0.117
CVD (%) 19.1 22.4 24.9 18.8 0.895
Continuous data are presented as means  SD and categorical data as percentages. bp, Blood pressure; Cig, cigarette; HbA1c, glycosylated hemoglobin; WHR, waist to
hip ratio.
a Partial (Pearson) correlations are age adjusted, except for age.
b P values are for partial correlation coefficients for continuous variables, or for the  2 test with P for linear-by-linear test for proportions.
c Product of number of cigarettes per day and years smoked.
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The results for the subgroup with available data for nonfatal
CVDeventswere similar to those from the entire study population.
In this subgroup, the age-adjustedHRs for all-causemortalitywere
0.98 (0.79–1.23) forwomenand1.17 (0.92–1.49) formenwithno
history of CVD at baseline, and 1.35 (0.98–1.86) for women and
1.16 (0.86–1.57) for men with prevalent CVD, and the age-ad-
justed HRs for CVD mortality were 0.81 (0.58–1.13) for women
and0.93 (0.64–1.34) formenwithoutCVD, and1.26 (0.80–1.99)
forwomen and 1.10 (0.75–1.62) formenwith prevalentCVD. For
nonfatal events theage-adjustedHRsper SDchange in logadiponec-
tinwere0.74(0.59–0.93) forwomenand0.91(0.73–1.14) formen
withoutCVDatbaseline,and0.73(0.54–0.99) inwomenand0.86
(0.65–1.14) inmenwithprevalentCVD.Baselinecharacteristics for
the subgroup with available data for nonfatal CVD events were
approximately identical to those of the entire study population
(data not shown).
Discussion
High adiponectinwas associatedwith a higher age and a beneficial
CVD risk profile at baseline in the general Dutch population. Risk
of nonfatal CVD was significantly reduced in women with higher
adiponectin, and there was a nonsignificant trend for such an as-
sociation in men. In contrast, high adiponectin was not associated
with lower CVD mortality and all-cause mortality, but after ad-
justment for cardiovascular risk factors, high adiponectin was sig-
nificantly associated with increased all-cause and cardiovascular
mortality. This association of high adiponectin and increasedmor-
tality risk was more pronounced in patients with prevalent CVD
than in those without. Adiponectin is considered to protect against
CVD, mediated by direct effects on the cardiovascular system and
by its association with a favorable cardiovascular risk profile (2).
Adiponectin inhibits pro-atherogenic processes in endothelial cells,
suppresses macrophage tofoam cell formation, and exerts antiin-
flammatory effects, e.g. through inhibition of nuclear factor-B.
Stimulation of AMP-activated kinase by adiponectin reduces insu-
lin resistance, and recentdata fromtheHoornStudy showthathigh
adiponectin levels are associated with a reduced risk of impaired
glucose tolerance and type 2 diabetes (1, 28). Furthermore, several
cross-sectional and genetic studies support the notion that low adi-
ponectin levels are associatedwith all components of themetabolic
syndrome and serve as a risk factor for coronary artery disease (1, 2).
TABLE 4. Multivariate-adjusted HRs (with 95% CI) for 15-yr CVD mortality in sex-specific quartiles of adiponectin
Adjusted for
Age, BMI,
WHR
Age, HDL,
triglycerides
Age, glucose,
2 h-glucose
Age,
insulin
Age,
ALT
Age, GFR,
smokinga
All
previous
Women (1220 study participants at risk with 83 deaths due to CVD)
First quartile 1.0 Reference 1.0 Reference 1.0 Reference 1.0 Reference 1.0 Reference 1.0 Reference 1.0 Reference
Second quartile 0.79 (0.42–1.51) 0.94 (0.49–1.79) 0.88 (0.42–1.86) 0.74 (0.39–1.41) 0.75 (0.40–1.41) 0.86 (0.45–1.69) 1.07 (0.49–2.34)
Third quartile 0.69 (0.36–1.34) 0.91 (0.45–1.82) 0.95 (0.46–1.93) 0.67 (0.34–1.29) 0.61 (0.32–1.17) 0.64 (0.33–1.24) 1.30 (0.60–2.81)
Fourth quartile 1.13 (0.63–2.02) 1.52 (0.81–2.84) 1.36 (0.72–2.65) 0.98 (0.56–1.72) 0.90 (0.52–1.57) 1.01 (0.57–1.78) 2.36 (1.13–4.95)
Continuousb 1.04 (0.88–1.31) 1.15 (0.90–1.46) 1.11 (0.87–1.41) 0.99 (0.80–1.23) 0.94 (0.76–1.16) 0.97 (0.79–1.20) 1.45 (1.10–1.92)
Men (1042 study participants at risk with 121 deaths due to CVD)
First quartile 1.0 Reference 1.0 Reference 1.0 Reference 1.0 Reference 1.0 Reference 1.0 Reference 1.0 Reference
Second quartile 1.13 (0.63–2.03) 1.31 (0.72–2.56) 1.20 (0.66–2.18) 1.12 (0.62–2.01) 1.13 (0.63–2.03) 1.10 (0.61–1.97) 1.21 (0.65–1.97)
Third quartile 1.54 (0.88–2.69) 1.61 (0.91–2.86) 1.44 (0.81–2.57) 1.30 (0.74–2.27) 1.33 (0.76–2.03) 1.30 (0.74–2.26) 1.59 (0.88–2.89)
Fourth quartile 1.43 (0.81–2.57) 1.51 (0.82–2.77) 1.24 (0.68–2.56) 1.17 (0.60–2.08) 1.13 (0.63–2.01) 1.12 (0.63–2.01) 1.71 (0.90–3.26)
Continuousb 1.19 (0.98–1.45) 1.20 (0.98–1.47) 1.10 (0.91–1.34) 1.09 (0.90–1.33) 1.07 (0.88–1.29) 1.08 (0.89–1.31) 1.30 (1.04–1.63)
WHR, Waist to hip ratio.
a Adjustment for current smokers (yes/no) and product of number of cigarettes per day and years smoked.
b HR per 1 SD change in log-transformed adiponectin.
TABLE 3. Age-adjusted HRs (with 95% CI) for 15-yr all-cause mortality, 15-yr CVD mortality, and 10-yr nonfatal CVD in sex-
specific quartiles of adiponectin
15-yr all-cause mortality 15-yr CVD mortality 10-yr nonfatal CVD
Women
Participants at risk 1248 1220 909
Events 219 83 128
First quartile 1.00 Reference 1.00 Reference 1.00 Reference
Second quartile 0.74 (0.50–1.10) 0.74 (0.40–1.39) 0.66 (0.42–1.06)
Third quartile 0.84 (0.58–1.23) 0.60 (0.31–1.15) 0.56 (0.36–0.91)
Fourth quartile 0.92 (0.64–1.31) 0.88 (0.51–1.53) 0.44 (0.27–0.72)
Continuousa 0.98 (0.86–1.12) 0.93 (0.75–1.15) 0.72 (0.61–0.90)
Men
Participants at risk 1077 1042 845
Events 286 121 195
First quartile 1.00 Reference 1.00 Reference 1.00 Reference
Second quartile 1.17 (0.80–1.73) 1.14 (0.64–2.03) 0.86 (0.57–1.30)
Third quartile 1.26 (0.87–1.82) 1.34 (0.77–2.33) 0.99 (0.67–1.46)
Fourth quartile 1.41 (0.98–2.03) 1.13 (0.64–2.00) 0.73 (0.47–1.11)
Continuousa 1.13 (1.00–1.28) 1.07 (0.89–1.29) 0.92 (0.79–1.06)
a HR per SD change in log-transformed adiponectin.
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However, several recent studies on the prospective associa-
tion between adiponectin and CVD events/mortality showed in-
consistent results (5–23). Unexpectedly, several of these studies,
in particular those including patients already afflicted with or at
high risk for CVD, found that high adiponectin was associated
with an increased risk of mortality (17, 18, 20–23). As an ex-
planation for these results, it was hypothesized that in CVD, a
counter-regulatory increase of adiponectin occurs that repre-
sents adefensemechanismof thebodyagainst the cardiovascular
alterations and the pro-inflammatory state associatedwithCVD
(24, 25).This is in linewithour results becausewe show that high
adiponectin is significantly associated with an increased mortal-
ity risk, in particular, in patients with prevalent CVD. These
findings fit well with observations that adiponectin exerts pro-
tective functions in early atherosclerosis by reducing a pro-
atherogenic endothelial activation, but in patients with vascular
diseases, adiponectin was positively correlated with serum con-
centrations of markers of endothelial activation/injury like
CD146 or vascular cell adhesion molecule-1, suggesting a pos-
sible up-regulation of adiponectin in response to endothelial
damage (2, 29, 30). It was also implicated that inflammation,
lipotoxicity, and oxidative stress increased adiponectin expres-
sion, whereas adiponectin counteracts these pro-atherogenic in-
fluences by its antiinflammatory and antioxidative properties (1,
2, 31–33). Furthermore, it was shown that adiponectin increases
in patientswithmyocardial dysfunction, although adiponectin is
suggested to protect against heart failure because it attenuates
cardiac hypertrophy (2, 18, 22, 23). All these data suggest that
adiponectin protects against CVD, but it may be compensatory
up-regulated in response to cardiovascular damage, or due to the
wasting process in heart failure with elevation of adiponectin as
a consequence ofweight loss (22).Weight loss andmalnutrition,
both associated with high adiponectin, predict mortality in pa-
tients with CVD, and could, therefore, partially account for the
relationship between high adiponectin andmortality (1, 34, 35).
Our results of an association between adiponectin andmortality
in patients with CVD fit well with the concept of “reverse epi-
demiology,” a term that is used to describe the inverse associa-
tion between traditional cardiovascular risk factors (e.g. BMI)
and mortality in patients with heart and renal failure (34, 35).
However, in the present study, adjustment for BMI did not ex-
plain the associations between adiponectin and mortality. Al-
ternatively, “adiponectin resistance,” possibly due to down-reg-
ulation of adiponectin receptors as reported in obesity and
insulinresistance,couldalsotriggeracounter-regulatory increaseof
adiponectin in high-risk patients with prevalent CVD (1).
It should alsobenoted that adiponectin serumconcentrations
are inversely correlated with GFR and are increased in patients
with albuminuria (18, 21, 29, 30). Underlying mechanisms for
the elevation of adiponectin in chronic kidney disease remain
unclear butmay at least in part be due to reduced renal clearance
(36). However, GFR in the present study could not explain the
association between high adiponectin and high mortality risk.
Apart from this, adiponectin correlates with age and might,
therefore, also be compensatory up-regulated in the aging pro-
cess of the body.
Finally, it cannot be excluded that adiponectin also exerts
harmful effects that contribute to the increased mortality risk
associated with high adiponectin. Toward this, it could be spec-
ulated that beneficial effects of adiponectin might become del-
eterious in advanced disease stages of CVD, in particular when
the compensatory increase of adiponectin is overwhelming. In
this context the ability of adiponectin to decrease body weight,
mediated by increases in energy expenditure and by central ef-
fects in the brain, might be harmful in advanced stages of CVD,
when a decline in body weight is associated with an adverse
cardiovascular outcome (1, 34, 35, 37). Considering that adi-
ponectin-mimetic therapies have been suggested to be intro-
duced in the treatment of metabolic and CVD (1, 2), it will be
important to elucidate the underlying mechanisms for the asso-
TABLE 5. Age- and sex-adjusted HRs (with 95% CI) for 15-yr all-cause mortality and 15-yr CVD mortality in subjects with and
without CVD at baseline in sex-specific quartiles of adiponectin
All Women Men
15-yr all-cause
mortality
15-yr CVD
mortality
15-yr all-cause
mortality
15-yr CVD
mortality
15-yr all-cause
mortality
15-yr CVD
mortality
No history of CVD
Participants at risk 1886 1839 1040 1015 846 824
Deaths 340 115 160 51 180 64
First quartile 1.0 Reference 1.0 Reference 1.0 Reference 1.0 Reference 1.0 Reference 1.0 Reference
Second quartile 0.73 (0.52–1.01) 0.64 (0.37–1.12) 0.58 (0.37–0.93) 0.64 (0.30–1.37) 0.96 (0.59–1.55) 0.73 (0.33–1.64)
Third quartile 0.89 (0.65–1.21) 0.72 (0.43–1.21) 0.70 (0.46–1.07) 0.42 (0.19–0.95) 1.19 (0.76–1.87) 1.18 (0.57–2.41)
Fourth quartile 0.96 (0.71–1.29) 0.77 (0.47–1.27) 0.73 (0.48–1.10) 0.64 (0.32–1.31) 1.32 (0.85–2.04) 1.03 (0.51–2.12)
Continuousa 1.00 (0.89–1.13) 0.90 (0.73–1.11) 0.90 (0.76–1.06) 0.79 (0.32–1.31) 1.14 (0.96–1.36) 1.07 (0.80–1.48)
History of CVD
Participants at risk 433 417 204 201 229 216
Deaths 164 88 59 32 105 56
First quartile 1.0 Reference 1.0 Reference 1.0 Reference 1.0 Reference 1.0 Reference 1.0 Reference
Second quartile 1.52 (0.92–2.50) 1.39 (0.71–2.74) 1.38 (0.64–2.99) 1.08 (0.36–3.22) 1.57 (0.80–3.05) 1.64 (0.67–4.04)
Third quartile 1.36 (0.82–2.26) 1.35 (0.68–2.66) 1.75 (0.77–3.99) 1.70 (0.59–5.32) 1.23 (0.63–2.39) 1.32 (0.54–3.27)
Fourth quartile 1.89 (1.16–3.06) 1.64 (0.85–3.17) 1.85 (0.91–3.76) 1.70 (0.67–4.29) 1.87 (0.95–3.67) 1.60 (0.63–4.11)
Continuousa 1.29 (1.07–1.55) 1.27 (0.98–1.63) 1.31 (1.00–1.72) 1.32 (0.91–1.91) 1.27 (0.99–1.63) 1.22 (0.87–1.73)
a HR per 1 SD change in log-transformed adiponectin.
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ciation between adiponectin andmortality, and tomonitor care-
fully therapeutic interventions that aim to enhance the secretion
or action of adiponectin.
Apart from low concentrations of a globular form that is
cleaved from the full-length protein, adiponectin forms multi-
mers that circulate in plasma in a low-, middle-, and high-mo-
lecular weight form (1, 2). These isoforms have different binding
affinities to the adiponectin receptors (AdipoR1 and AdipoR2)
and may, therefore, exert different bioactivities. Recent data in-
dicate that the high-molecularweight form is themost active and
clinically relevant form, at least for the metabolic and vascular-
protective effects of adiponectin (1, 2, 38, 39). However, it was
shown that globular adiponectin may contribute to myocardial
hypertrophy, suggesting that not all isoformsof adiponectin pro-
tect against CVD (40).
A limitation of the present study may be that the different
isoforms of adiponectin were not determined because at the
time of our measurements, the recently developed ELISA sys-
tems were not available (39). Furthermore, information on
nonfatal CVD was available for a subpopulation, and for a
shorter follow-up period. To exclude the possibility that the
differences in population size and follow-up duration explain
the differences in the associations between adiponectin and
nonfatal CVD and mortality, we also studied 10-yr all-cause
and CVD mortality in the same subcohort. The associations
did not differ from those observed in the total cohort, and for
a longer follow-up duration.
During the revision process of our manuscript, other data
from older men were published that confirm a positive associa-
tion between adiponectin and mortality, with the most signifi-
cant results for patients with heart failure (41).
In conclusion, high plasma adiponectin level is associated
with a favorable lipid and glucose metabolism, and with a re-
duced risk of CVD events inwomen.However, higher adiponec-
tin was associated with an increased risk of mortality, in partic-
ular in people with a history of CVD. We hypothesize that
adiponectin protects against metabolic and vascular diseases,
but in patients already afflicted with CVD, adiponectin is com-
pensatory up-regulated in advanced disease stages and, there-
fore, indicates a high mortality risk in these patients. It remains
a challenge for the near future to elucidate further the underlying
mechanisms for our results.
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